Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

1(16.7%)

Early Phase 1

1(16.7%)

6Total

Phase 1(4)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03073395Phase 1Completed

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Role: lead

NCT05381103Phase 2Recruiting

PSMA-PET to Guide Prostatectomy

Role: lead

NCT02826382Early Phase 1Completed

Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

Role: lead

NCT03903549Phase 1Completed

Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers

Role: lead

NCT03444844Phase 1Active Not Recruiting

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Role: lead

NCT03902548Phase 1Completed

Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers

Role: lead

All 6 trials loaded